AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application.

1. (Currently amended) A compound of the formula I,

wherein:

 R^{1} is aryl or heteroaryl, each of-which is optionally substituted one or more times by C_{1} - C_{6} -alkyl, halogen, CF_{3} , C_{1} - C_{6} -alkoxy, C_{1} - C_{6} -alkylmercapto, -CN, $COOR^{10}$, $CONR^{16}R^{12}$, $NR^{18}R^{14}$, $S(O)_{m}R^{15}$ or $S(O)_{5}NR^{16}R^{17}$:

R² is aryl-or-heteroaryl, oxazolyl, thiazolyl or pyrrolyl, each of which is optionally substituted one or more times by:

halogen, -CN, -NH₂, C₃-C₅-alkandiyl, phenyl, heteroaryl, aryl-substituted C₁-C₄-alkyl, heteroaryl-substituted C₁-C₄-alkyl, -CF₃, -NO₂, -OH, phenoxy, benzyloxy, (C₁-C₁₀-alkyl)-COO-, -S(O)₁₀R²⁰, -SH, phenylamino, benzylamino, (C₁-C₁₀-alkyl)-CONH-, (C₁-C₁₀-alkyl)-CO-N(C₁-C₄-alkyl)-, phenyl-CONH-, phenyl-CO-N(C₁-C₄-alkyl)-, heteroaryl-CONH-, beteroaryl-CO-N(C₁-C₄-alkyl)-, (C₁-C₁₀-alkyl)-CO-, phenyl-CO-, heteroaryl-CO-, CF₃-CO-, -OCH₂O-, -OCF₂O-, -OCH₂CO-, -CH₂CH₂O-, -COOR²¹, -CONR²²R²³, -C(NH)-NH₂, -SO₂NR²⁴R²⁵, R²⁶SO₂NH-, R²⁷SO₂N(C₁-C₆-alkyl)-,

optionally substituted C₁-C₁₀-alkyl, optionally substituted C₂-C₁₀-alkenyl, optionally substituted C₂-C₁₀-alkynyl, optionally substituted C₁-C₁₀-alkoxy, optionally substituted C₁-C₁₀-alkylamino, optionally substituted di(C₁-C₁₀-alkyl)amino, wherein the optional substituents of the optionally substituted substituents are selected from one or more of the group consisting of F, OH, C₁-C₈-alkoxy, aryloxy, C₁-C₈-alkylmercapto, NH₂, C₁-C₈-alkylamino and di(C₁-C₈-alkyl)amino, or

a residue of a saturated or partially unsaturated aliphatic monocyclic 5- to 7-membered heterocycle containing 1, 2 or 3 heteroatoms selected from the group consisting of N, O and S, wherein the heterocycle is optionally substituted one or more times by halogen, C₁-C₃-alkyl, C₁-C₃-alkoxy, OH, oxo or CF₃, and wherein the heterocycle is optionally condensed to the aryl group or heteroaryl group representing R², and

wherein for each aryl-or heteroaryl-oxazolyl, thiazolyl or pyrrolyl as R² bearing an aryl, heteroaryl, phenyl, aryl-containing, heteroaryl-containing or phenyl-containing group as an optional substituent, that each aryl, heteroaryl, phenyl, aryl-containing, heteroaryl-containing and phenyl-

containing group is optionally substituted one or more times by halogen, -CN, C_1 - C_3 -alkyl, OH, C_1 - C_3 -alkoxy or CF_3 ;

 R^{10} is H, C_1 - C_6 -alkyl or benzyl, wherein the phenyl group of the benzyl is optionally substituted one or more times by halogen, -CN, C_1 - C_3 -alkyl, C_1 - C_3 -alkoxy or CF_3 ;

 R^{11} is H, C_1 - C_6 -alkyl, which is optionally substituted by phenyl, phenyl, indanyl or heteroaryl, wherein each phenyl, indanyl and heteroaryl is optionally substituted one or more times by halogen, -CN, C_1 - C_3 -alkyl, C_1 - C_3 -alkoxy or CF_3 ;

optionally substituted phenyl, optionally substituted benzyl, optionally substituted heteroaryl, optionally substituted phenyl-CO-, or optionally substituted heteroaryl-CO-, wherein the optional substituents of the optionally substituted substitutents are selected from one or more of the group consisting of halogen, -CN, C_1 - C_3 -alkyl, C_1 - C_3 -alkoxy and CF_3 ;

$$R^{15}$$
 is C_1 - C_6 -alkyl, CF_3 ,

optionally substituted phenyl or optionally substituted heteroaryl, wherein the optional substituents of the optionally substituted substituents are selected from one or more of the group consisting of halogen, -CN, C_3 -alkyl, C_4 - C_3 -alkoxy and CF_3 ;

R¹⁶ is H, C₁-C₆-alkyl, which is optionally substituted by phenyl, phenyl, indanyl or heteroaryl, wherein each phenyl, indanyl, and heteroaryl is optionally substituted one or more times by halogen, -CN, C₁-C₃-alkyl, C₁-C₃-alkoxy or CF₃;

 $R^{20} \ is \ C_1\text{--}C_{10}\text{--alkyl}, \ which \ is \ optionally \ substituted \ one \ or \ more \ times \ by \ F, \ OH, \ C_1\text{--}C_8\text{--alkyl}, \ aryloxy, \ C_1\text{--}C_8\text{--alkyl} \ arnino, \ or \ di(C_1\text{--}C_8\text{--alkyl}) \ amino, \ CF_3,$

optionally substituted phenyl or optionally substituted heteroaryl, wherein the optional substituents of the optionally substituted phenyl and heteroaryl are selected from one or more of the group consisting of halogen, -CN, C_1 - C_3 -alkyl, C_1 - C_3 -alkoxy and CF_3 ;

$$\mathbb{R}^{21}$$
 is H.

 C_1 - C_{10} -alkyl, which is optionally substituted one or more times by F, C_1 - C_8 -alkoxy or di(C_1 - C_8 -alkyl)amino,

aryl- $(C_1$ - C_4 -alkyl)- or heteroaryl- $(C_1$ - C_4 -alkyl)-, wherein each of the aryl- $(C_1$ - C_4 -alkyl)- or heteroaryl- $(C_1$ - C_4 -alkyl)- is optionally substituted one or more times by halogen, C_1 - C_4 -alkyl, C_1 - C_4 -alkoxy or di $(C_1$ - C_6 -alkyl)amino;

 R^{22} is H, C_1 - C_{10} -alkyl, which is optionally substituted one or more times by F, C_1 - C_8 -alkoxy, di(C_1 - C_8 -alkyl)amino or phenyl,

phenyl, indanyl or heteroaryl, wherein each phenyl, indanyl and heteroaryl is optionally substituted one or more times by halogen, -CN, C_1 - C_3 -alkyl, C_1 - C_3 -alkoxy or CF_3 ;

$$R^{23}$$
 is H or C_1 - C_{10} -alkyl;

 R^{24} is H, C_1 - C_{10} -alkyl, which is optionally substituted one or more times by F, C_1 - C_8 -alkoxy, $di(C_1$ - C_8 -alkyl)amino or phenyl,

phenyl, indanyl or heteroaryl, wherein each phenyl, indanyl and heteroaryl is optionally substituted one or more times by halogen, -CN, C_1 - C_3 -alkyl, C_1 - C_3 -alkoxy or CF_3 ;

 $R^{26} \ is \ C_1\text{-}C_{10}\text{-}alkyl, \ which \ is \ optionally \ substituted \ one \ or \ more \ times \ by \ F, \ OH,$ $C_1\text{-}C_8\text{-}alkoxy, \ aryloxy, \ C_1\text{-}C_8\text{-}alkylmercapto, \ C_1\text{-}C_8\text{-}alkylamino, \ or \ di(C_1\text{-}C_8\text{-}alkyl)amino, \ CF_3,$

optionally substituted phenyl or optionally substituted heteroaryl, wherein the optional substituents of the optionally substituted phenyl and heteroaryl are selected from one or more of the group consisting of halogen, -CN, C_1 - C_3 -alkyl, C_4 - C_3 -alkoxy and CF_3 .

 R^{27} is C_1 - C_{10} -alkyl, which is optionally substituted one or more times by F, OH, C_1 - C_8 -alkoxy, aryloxy, C_1 - C_8 -alkylmercapto, C_1 - C_8 -alkylamino, or di(C_1 - C_8 -alkyl)amino, CF_3 ,

optionally substituted phenyl or optionally substituted heteroaryl, wherein the optional substituents of the optionally substituted phenyl and heteroaryl are selected from one or more of the group consisting of halogen, -CN, C_1 - C_3 -alkyl, C_4 - C_3 -alkoxy and CF_3 ,

wherein heteroaryl is a residue of a 5-membered to 10-membered, aromatic, monocyclic or bicyclic heterocycle containing one or more heteroatoms selected from the group consisting of N, O and S;

wherein aryl is phenyl, naphth-1-yl or naphth-2-yl;

m is 0, 1 or 2; and

n is 1, 2, or 3-or 4;


or a stereoisomer or a mixture of stereoisomers in any ratio of the compound, or a pharmaceutically acceptable salt of the compound, stereoisomer or mixture of stereoisomers of the compound;

provided that when R⁴ is unsubstituted phenyl, then R² is other than unsubstituted phenyl, 4-bromophenyl, 3-methoxyphenyl, chlorosubstituted 4H thieno[3,2-b]pyrrol-5-yl, unsubstituted thienyl, naphthyridinyl, unsubstituted pyridinyl, 3-hydroxy-4-methoxypyridin-2-yl, 2,6-dichloropyridin-4-yl or 3,4,5-trimethoxyphenyl.

- 2. (Original) The compound according to claim I wherein R¹ is optionally substituted phenyl.
- 3. (Cancelled)
- 4. (Original) The compound according to claim 1 wherein n is 1.
- 5. (Original) The compound according to claim 1 wherein n is 3.
- 6. (Currently amended) The compound according to claim 1 wherein R^2 is phenyl or heteroaryl, oxazolyl, thiazolyl or pyrrolyl, each of which is optionally substituted one or more times by F, Cl, Br, C_1 - C_3 -alkyl, C_4 - C_5 -alkoxymethyl, 2-amino-3,3,3-trifluoropropyl-, CF_3 , C_5 -C $_5$ -alkandiyl, phenyl, heteroaryl, benzyl, heteroaryl-methyl-, OH, C_4 -C $_3$ -alkoxy, phenoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, $(C_4$ -C $_4$ -alkyl)-COO, C_4 -C $_3$ -alkylmercapto, phenylmercapto, C_4 -C $_3$ -alkylsulfonyl, phenylsulfonyl, NH_2 , C_4 -C $_4$ -alkylamino, $di(C_4$ -C $_4$ -alkyl)-amino, $(C_4$ -C $_3$ -alkyl)-CONH-, $(C_4$ -alkyl)-SO $_2$ NH-, $(C_4$ -C $_3$ -alkyl)-CO-, phenyl-CO-, $-OCH_2O$ -, $-OCF_2O$ -, $-CH_2CH_2O$ -, $-COO(C_4$ -C $_4$ -alkyl), $-CONH_2$, $-CONH(C_4$ -C $_4$ -alkyl), $-CON(di(C_4$ -C $_4$ -alkyl)), -CN, $-SO_2NH_2$, $-SO_2NH(C_4$ -C $_4$ -alkyl), $-SO_2N(di(C_4$ -C $_4$ -alkyl)), pyrrolidinyl, piperidinyl, morpholinyl or thiomorpholinyl, and

wherein for each aryl-or-heteroaryl-oxazolyl, thiazolyl or pyrrolyl as R^2 bearing an heteroaryl, phenyl, heteroaryl-containing or phenyl-containing group as an optional substituent, that each heteroaryl, phenyl, heteroaryl-containing and phenyl-containing group is optionally substituted one or more times by halogen, -CN, C_1 - C_3 -alkyl, OH, C_1 - C_3 -alkoxy or CF_3 .

7. (Currently amended) A pharmaceutical preparation composition, comprising a pharmaceutically effective amount of athe compound according to claim 1 of formula I.



wherein:

R³ is anyl or beteroaryl, each of which is optionally substituted one or more times by C₄-C₆-alkyl, halogen, CF₃, C₄-C₆-alkoxy, C₄-C₆-alkylmercapto, CN, COOR⁴⁰, CONR⁴⁴R⁴², NR⁴³R⁴⁴, S(O)₆R⁴⁵ or S(O)₂NR⁴⁶R⁴⁷;

R² is anyl-or heteroaryl, each of which is optionally substituted one or more times by halogen. CN, NH₂, C₃, C₅ alkandiyl, phenyl, heteroaryl, anyl-substituted C₄, C₄, alkyl,

heteroaryl substituted C_4 C_4 alkyl, CF_4 , NO_2 , OH, phenoxy, benzyloxy, $(C_4$ C_{10} alkyl) COO, $S(O)_m R^{20}$, SH, phenylamino, benzylamino, $(C_4$ C_{40} alkyl) CONH, $(C_4$ C_{40} alkyl) CONH, phenyl CONH, phenyl CONH, phenyl CONH, heteroaryl $CON(C_4$ C_4 alkyl), heteroaryl CONH, heteroaryl CONH, heteroaryl $CONH^{22}$, $CONH^{23}$,

optionally substituted C_1 - C_{10} -alkyl, optionally substituted C_2 - C_{10} -alkynyl, optionally substituted C_1 - C_{10} -alkynyl, optionally substituted C_1 - C_{10} -alkylamino, optionally substituted C_1 - C_{10} -alkylamino, optionally substituted di(C_1 - C_{10} -alkylamino, wherein the optional substituents of the optionally substituted substituents are selected from one or more of the group consisting of F, OH, C_1 - C_2 -alkoxy, aryloxy, C_4 - C_3 -alkylamino and di(C_4 - C_8 -alkylamino, or

a residue of a saturated or partially unsaturated aliphatic monocyclic 5- to 7-membered heterocycle containing 1, 2 or 3-heteroatoms selected from the group consisting of N. O and S, wherein the heterocycle is optionally substituted one or more times by halogen, C, C, alkyl, C, C, alkoxy, OH, oxo or CF, and wherein the heterocycle is optionally condensed to the aryl-group or heterocryl-group representing R³, and

wherein for each aryl or heteroaryl as R² bearing an aryl, heteroaryl, phenyl, aryl containing, heteroaryl containing or phenyl containing group as an optional substituent, that each aryl, heteroaryl, phenyl, aryl containing, heteroaryl containing and phenyl containing group is optionally substituted one or more times by halogen. CN, C₁, C₂, alkyl, OH, C₁, C₃ alkoxy or CF₃;

 R^{40} is H, C_4 - C_6 -alkyl or benzyl, wherein the phenyl group of the benzyl is optionally substituted one or more times by halogen, CN, C_4 - C_5 -alkyl, C_4 - C_4 -alkoxy or CF_{57}

R¹⁴ is H, C₄ C₆ alkyl, which is optionally substituted by phenyl, phenyl, indanyl or heteroaryl, wherein each phenyl, indanyl and heteroaryl is optionally substituted one or more times by halogen, CN, C₄ -C₃ alkyl, C₄ -C₃ alkoxy or CF₄;

optionally substituted phenyl, optionally substituted benzyl, optionally substituted heteroaryl CO, wherein the optional substitutents of the optionally substituted substitutents are selected from one or more of the group consisting of halogen. CN, C₁-C₂-alkyl, C₁-C₃-alkoxy and CF₃:

optionally substituted phenyl or optionally substituted heteroaryl, wherein the optional substituents of the optionally substituted substituents are selected from one or more of the group consisting of halogen. CN, C_4 - C_5 -alkoxy and CF_{23}

R¹⁶ is H, C₄-C₆-alkyl, which is optionally substituted by phenyl, phenyl, indanyl or heteroaryl, wherein each phenyl, indanyl, and heteroaryl is optionally substituted one or more times by halogen, CN, C₄-C₅-alkyl, C₄-C₅-alkoxy or CF₅;

 R^{30} is C_1 - C_{10} alkyl, which is optionally substituted one or more times by F_1 -OH, C_2 - C_3 -alkylmereapto, C_4 - C_8 -alkylamino, or $di(C_4$ - C_8 -alkylamino, CF_{37}

optionally substituted phenyl or optionally substituted heteroaryl, wherein the optional substituents of the optionally substituted phenyl and heteroaryl are selected from one or more of the group consisting of halogen. CN, C₄-C₅-aikyl, C₄-C₅-aikoxy and CF₅.

 C_4 - C_{40} -alkyl, which is optionally substituted one or more times by F, C_4 - C_8 -alkoxy or $di(C_1$ - C_8 -alkyl)amino,

 $aryl\cdot (C_1\cdot C_4\cdot alkyl) \quad \text{or heteroaryl} \cdot (C_1\cdot C_4\cdot alkyl) \quad \text{, wherein each of the aryl} \cdot (C_4\cdot C_4\cdot alkyl) \quad \text{or heteroaryl} \cdot (C_4\cdot C_4\cdot alkyl) \quad \text{is optionally substituted one or more times by halogen, } C_4\cdot C_4\cdot alkyl, \\ C_4\cdot C_4\cdot alkyl) \quad \text{and } C_4\cdot C_4\cdot alkyl) \quad \text{and }$

 \mathbb{R}^{22} is H, \mathbb{C}_4 G₄₀ alkyl, which is optionally substituted one or more times by F, \mathbb{C}_4 G₈ alkoxy, $di(\mathbb{C}_4, \mathbb{C}_8)$ alkyl)amino or phenyl,

phenyl, indanyl or heteroaryl, wherein each phenyl, indanyl and heteroaryl is optionally substituted one or more times by halogen. CN, C₁-C₂ alkyl, C₁-C₃ alkoxy or CF₂;

 \mathbb{R}^{24} is H, C₄-C₄₀ alkyl, which is optionally substituted one or more times by F, C₄-C₈ alkoxy, di(C₄-C₈-alkyl)amino or phenyl,

phenyl, indanyl or heteroaryl, wherein each phenyl, indanyl and heteroaryl is optionally substituted one or more times by halogen. CN, C₁-C₂-alkyl, C₁-C₃-alkoxy or CF₃;

R²⁶ is C₁·C₁₀ alkyl, which is optionally substituted one or more times by F, OH,
C₂·C₃ alkoxy, aryloxy, C₄·C₈ alkylmercapto, C₄·C₈ alkylamino, or di(C₄·C₈ alkyl)amino,
CF₂₇

optionally substituted phenyl or optionally substituted heteroaryl, wherein the optional substituents of the optionally substituted phenyl and beteroaryl are selected from one or more of the group consisting of halogen. CN, C₁-C₂-alkyl, C₄-C₅-alkoxy and CF₅.

 R^{27} is C_4 - C_{46} -alkyl, which is optionally substituted one or more times by F. OH, C_4 - C_8 -alkoxy, aryloxy, C_4 - C_8 -alkylmercapto, C_4 - C_8 -alkylamino, or di(C_4 - C_8 -alkyl)amino, CF_{27}

optionally-substituted phenyl or optionally substituted heteroaryl, wherein the optional substituents of the optionally substituted phenyl and heteroaryl are selected from one or more of the group consisting of halogen. CN, C₂-C₃-alkyl, C₄-C₃-alkoxy and CF₃.

wherein heteroaryl is a residue of a 5-membered to 10-membered, aromatic, monocyclic or bicyclic heterocycle containing one or more heteroatoms selected from the group consisting of N. O and S;

wherein aryl is phenyl, naphth 1 yl or naphth 2 yl;


m is 0, 1 or 2; and

n is 1, 2, 3 or 4;

or a stereoisomer or a mixture of stereoisomers in any ratio of the compound, or a pharmaceutically acceptable salt of the compound, stereoisomer or mixture of stereoisomers of the compound;

and a pharmaceutically acceptable carrier.

8. (Withdrawn-currently amended) A method for the stimulation of the expression of endothelial NO synthase, in a patient in need thereof, comprising administering to such patient a pharmaceutically effective amount of athe compound according to claim 1 of formula I.



wherein:

R* is anyl-or-heteroaryl, each of which is optionally substituted one or more times by C₄-C₆-alkyl, halogen, CF₃, C₄-C₆-alkoxy, C₄-C₆-alkylmercapto, CN, COOR¹⁶, CONR¹⁴R¹², NR¹³R¹⁴, S(O)₃R⁴⁵ or S(O)₂NR⁴⁵R⁴²;

 R^2 is anyl-or-heteroaryl, each of which is optionally substituted one or more times by halogen, CN, NH_a , C_a , C_b -alkandiyl, phenyl, heteroaryl, anyl-substituted C_4 , C_4 -alkyl,

heteroaryl substituted C₄-C₄-alkyl, CF₂, NO₂, OH, phenoxy, benzyloxy, (C₄-C₁₀-alkyl) COO., S(O)_mR²⁶,—SH, phenylamino, benzylamino, (C₄-C₁₀-alkyl) CONH., (C₄-C₁₀-alkyl) CO-N(C₄-C₄-alkyl), phenyl-CONH., phenyl-CO-N(C₄-C₄-alkyl), heteroaryl-CONH., heteroaryl-CO-N(C₄-C₄-alkyl), (C₄-C₁₀-alkyl) CO-, phenyl-CO-, heteroaryl-CO-, CF₃-CO-, OCH₂O-, OCH₂CH₂O-, CH₂CH₂O-, COOR²¹, CONR²²R²³,—C(NH)-NH₂, SO₂NR²⁴R²⁵, R²⁶SO₂NH., R²²SO₂N(C₄-C₆-alkyl).

optionally substituted C_4 - C_{10} -alkyl, optionally substituted C_2 - C_{40} -alkenyl, optionally substituted C_4 - C_{10} -alkynyl, optionally substituted C_4 - C_{10} -alkylamino, optionally substituted C_4 - C_{10} -alkylamino, wherein the optional substituents of the optionally substituted substituents are selected from one or more of the group consisting of F, OH, C_4 - C_8 -alkeylamino and di(C_4 - C_8 -alkylamino, or

a residue of a saturated or partially unsaturated aliphatic monocyclic 5 to 7 membered heterocycle containing 1, 2 or 3 heteroatoms selected from the group consisting of N, O and S, wherein the heterocycle is optionally substituted one or more times by halogen, C₁-C₂ alkyl, C₄-C₅ alkoxy, OH, oxo or CF₅, and wherein the heterocycle is optionally condensed to the aryl group or heterocycle group representing R², and

wherein for each aryl-or heteroaryl as R² bearing an aryl, heteroaryl, phenyl, aryl-containing, heteroaryl-containing or phenyl-containing group as an optional substituent, that each aryl, heteroaryl, phenyl, aryl-containing, heteroaryl-containing and phenyl-containing group is optionally substituted one or more times by halogen. CN, C₁-C₂-alkyl, OH, C₁-C₂-alkoxy or CF₃;

 R^{10} is $H, C_4 \cdot C_6$ alkyl or benzyl, wherein the phenyl group of the benzyl is optionally substituted one or more times by halogen, $CN, C_4 \cdot C_5$ alkyl, $C_4 \cdot C_4$ alkoyy or CF_{35}

R is H, C, C, alkyl, which is optionally substituted by phenyl, phenyl, indanyl or

heteroaryl, wherein each phenyl, indanyl and heteroaryl is optionally substituted one or more times by halogen. CN, C₄, C₃ alkyl, C₄, C₅ alkoxy or CF₂:

optionally substituted phenyl, optionally substituted benzyl, optionally substituted heteroaryl CO, wherein the optional substituents of the optionally substituted substituents are selected from one or more of the group consisting of halogen. CN, C₁, C₂, alkyl, C₃, C₄, alkoxy and CF₂:

optionally substituted phenyl or optionally substituted heteroaryl, wherein the optional substituents of the optionally substituted substituents are selected from one or more of the group consisting of halogen, $-CN_rC_4$ - $-C_3$ -alkeyl, $-C_4$ -alkeyl and $-CP_3$:

R¹⁶ is H, C₄ C₆ alkyl, which is optionally substituted by phenyl, phenyl, indanyl or heteroaryl, wherein each phenyl, indanyl, and beteroaryl is optionally substituted one or more times by halogen, CN, C₄ C₅ alkyl, C₄ C₄ alkoxy or CF₅:

 $R^{20} \hbox{ is C_4-C_{40}-alkyl, which is optionally substituted one or more times by F_*-OH,} \\ C_4 \cdot C_8 \hbox{-alkoxy, aryloxy, C_4-C_8-alkylmercapto, C_4-C_8-alkylamino, or $di(C_4$-C_8-alkyl)amino,} \\$

optionally substituted phenyl or optionally substituted heteroaryl, wherein the optional substituents of the optionally substituted phenyl and heteroaryl are selected from one or more of the group consisting of halogen. CN, C₁, C₃ alkyl, C₄, C₅ alkoxy and CF₂.

CF.

 C_4 C_{40} alkyl, which is optionally substituted one or more times by F, C_4 C_8 alkoxy or $di(C_4$ C_8 -alkyl)amino.

aryl (C_4 - C_4 -alkyl) or heteroaryl (C_4 - C_4 -alkyl), wherein each of the aryl (C_4 - C_4 -alkyl) or heteroaryl-(C_4 - C_4 -alkyl) is optionally substituted one or more times by halogen, C_4 - C_4 -alkyl, C_4 - C_4 -alkoxy or di(C_4 - C_6 -alkyl)amino;

 R^{23} is H, C_4 C_{40} alkyl, which is optionally substituted one or more times by F, C_4 C_8 alkoxy, $di(C_4$ C_8 alkyl)amino or phonyl,

phenyl, indanyl or heteroaryl, wherein each phenyl, indanyl and heteroaryl is optionally substituted one or more times by halogen. CN, C₄-C₅ alkyl, C₁-C₅ alkoxy or CF₅:

 R^{24} is H. C_4 C_{16} alkyl, which is optionally substituted one or more times by F. C_4 C_8 alkoxy, $di(C_4$ C_8 alkyl)amino or phenyl,

phenyl, indanyl or heteroaryl, wherein each phenyl, indanyl and heteroaryl is optionally substituted one or more times by halogen. CN, C₁-C₂ alkyl, C₁-C₂ alkoxy or CF₂:

 R^{26} is C_4 - C_{10} alkyl, which is optionally substituted one or more times by F, OH, C_4 - C_4 alkoxy, aryloxy, C_4 - C_8 alkylmercapto, C_4 - C_8 alkylamino, or $di(C_1$ - C_8 alkyl)amino, CF_{37}

optionally substituted phenyl or optionally substituted heteroaryl, wherein the optional substituents of the optionally substituted phenyl and heteroaryl are selected from one or more of the group consisting of hulogen, CN, C₁, C₃ alkyl, C₄, C₃ alkoxy and CF₃.

 $R^{27} \text{ is } C_4 \cdot C_{40} \text{ alkyl, which is optionally substituted one or more times by F. OH,} \\ C_4 \cdot C_8 \cdot \text{alkoxy, aryloxy, } C_4 \cdot C_8 \cdot \text{alkylmercapto, } C_4 \cdot C_8 \cdot \text{alkylamino, or } \text{di}(C_4 \cdot C_8 \cdot \text{alkylamino,}) \\ CF_{35}$

optionally-substituted-phenyl-or optionally substituted beteroaryl, wherein the optional substituents of the optionally substituted phenyl and beteroaryl are selected from one or more of the group consisting of balogen, CN, C_1 , C_3 alkyl, C_4 , C_4 alkoxy and CF_{3*}

wherein heteroaryl is a residue of a 5-membered to 10-membered, aromatic, monocyclic or bicyclic heterocycle containing one or more heteroatoms selected from the group consisting of N; O and S;

wherein aryl is phenyl, naphth 1 yl or naphth 2 yl;

m is 0, 1 or 2; and

n is 1, 2, 3 or 4;

or a stereoisomer or a mixture of stereoisomers in any ratio of the compound, or a pharmaceutically acceptable salt of the compound, stereoisomer or mixture of stereoisomers of the compound.

9. (Withdrawn-currently amended) A method for treatment of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothel damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance or a restricted ability to learn, or for the lowering of cardiovascular risk of postmenopausal women or of women taking contraceptives, in a patient in need thereof, comprising administering to such patient a pharmaceutically effective amount of athe compound according to claim 1 of formula 1;

wherein:

R¹ is aryl or heteroaryl, each of which is optionally substituted one or more times by C₂, C₈ alkyl, halogen, CF₃, C₄, C₆ alkoxy, C₄, C₆ alkylmercapto, CN, COOR¹⁰, CONR¹¹R¹², NR¹³R¹⁴, S(O)₈R¹⁵ or S(O)₂NR¹⁵R¹⁴;

 R^2 is anyl-or heteroaryl, each of which is optionally substituted one or more times by halogen, CN, NH_2 , C_3 - C_4 -alkyl, heteroaryl, anyl-substituted C_4 - C_4 -alkyl,

heteroaryl substituted C_1 - C_4 -alkyl, CF_3 , NO_2 , OH, phenoxy, benzyloxy, $(C_1$ - C_{10} -alkyl) COO-, $S(O)_m R^{20}$, SH, phenylamino, benzylamino, $(C_1$ - C_{10} -alkyl) CONH-, $(C_1$ - C_{10} -alkyl) $CON(C_1$ - C_4 -alkyl) , phenyl-CONH-, phenyl- $CON(C_4$ - C_4 -alkyl) , $(C_4$ - C_{40} -alkyl) CO-, phenyl-CO-, heteroaryl-CO-, CF_3 -CO-, CCF_3 -, CCF_3

optionally substituted C_4 C_{40} alkyl, optionally substituted C_2 C_{40} alkenyl, optionally substituted C_4 C_{40} alkynyl, optionally substituted C_4 C_{40} alkyl) amino, wherein the optional substitutents of the optionally substituted substituted are selected from one or more of the group consisting of F, OH, C_4 C_8 alkoxy, aryloxy, C_4 C_8 alkylmercapto, NH_2 , C_4 C_8 alkylamino and $di(C_4$ C_8 alkylamino, or

a residue of a saturated or partially unsaturated aliphatic monocyclic 5—to 7-membered heterocycle containing 1, 2 or 3 heteroatoms selected from the group consisting of N, O and S, wherein the heterocycle is

optionally substituted one or more times by halogen, C_4 , C_3 alkyl, C_4 , C_5 alkoxy, OH, exe or CF_4 , and wherein the heterocycle is optionally condensed to the aryl group or heterocryl group representing \mathbb{R}^2 , and

wherein for each aryl-or heteroaryl as R² bearing an aryl, heteroaryl, phenyl, aryl-containing, heteroaryl containing or phenyl-containing group as an optional substituent, that each aryl, heteroaryl, phenyl, aryl-containing, heteroaryl-containing and phenyl-containing group is optionally substituted one or more times by halogen. CN, C₁-C₂-alkyl, OH, C₁-C₃-alkoxy or CF₃:

 R^{10} is H, C_1, C_6 alkyl or benzyl, wherein the phenyl group of the benzyl is optionally substituted one or more times by halogen, CN, C_1, C_3 alkyl, C_1, C_4 alkoxy or CF_4 :

R¹⁴ is H, C₁ C₆ alkyl, which is optionally substituted by phenyl, indanyl or heteroaryl, wherein each phenyl, indanyl and heteroaryl is optionally substituted one or more times by halogen. CN, C₁ C₂ alkyl, C₁ C₃ alkoxy or CF₃;

optionally substituted phenyl, optionally substituted benzyl, optionally substituted heteroaryl. CO., wherein the optional substituents of the optionally substituted substitutents are selected from one or more of the group consisting of halogen. CN, C₁-C₂ alkyl, C₁-C₂ alkoxy and CF₂:

optionally substituted phenyl or optionally substituted beteroaryl, wherein the optional substituents of the optionally substituted substituents are selected from one or more of the group consisting of halogen, -CN, C₄-C₅-alkoy, and CF₂:

R¹⁶ is H. C₄-C₆-alkyl, which is optionally substituted by phenyl, phenyl, indanyl or heteroaryl, wherein each phenyl, indanyl, and heteroaryl is optionally substituted one or more times by halogen. CN, C₄-C₄-alkyl, C₄-C₅-alkoxy or CF₅:

R³⁰ is C₄-C₄₀ alkyl, which is optionally substituted one or more times by F, OH, C₄-C₅-alkoxy, aryloxy, C₄-C₆-alkylmercupto, C₄-C₅-alkylamino, or di(C₄-C₅-alkyl)amino,

CE35

optionally substituted phenyl or optionally substituted heteroaryl, wherein the optional substituents of the optionally substituted phenyl and heteroaryl are selected from one or more of the group consisting of halogen, CN, C₁-C₂ alkyl, C₄-C₃ alkoxy and CF₃.

 $C_4 \cdot C_{40}$ alkyl, which is optionally substituted one or more times by F, $C_4 \cdot C_8$ alkoxy or $di(C_4 \cdot C_8)$ alkyl)amino;

 $airyl \cdot (C_1 \cdot C_4 \cdot alkyl)$ or heteroaryl $\cdot (C_4 \cdot C_4 \cdot alkyl)$, wherein each of the aryl $\cdot (C_4 \cdot C_4 \cdot alkyl)$ or heteroaryl $\cdot (C_4 \cdot C_4 \cdot alkyl)$ is optionally substituted one or more times by halogen, $\cdot C_4 \cdot C_4 \cdot alkyl$, $\cdot C_4 \cdot alkyl$, $\cdot C_4 \cdot alkyl$) araino;

 \mathbb{R}^{22} is H, \mathbb{C}_4 \mathbb{C}_{10} alkyl, which is optionally substituted one or more times by F, \mathbb{C}_4 \mathbb{C}_8 alkoxy, $\mathbb{d}_1(\mathbb{C}_4,\mathbb{C}_8)$ alkyl)amino or phenyl.

phenyl, indanyl or heteroaryl, wherein each phenyl, indanyl and heteroaryl is optionally substituted one or more times by halogen. CN, C₄-C₃ alkyl, C₄-C₅ alkoxy or CF₅;

 R^{24} is H, C_1 - C_{10} -alkyl, which is optionally substituted one or more times by F, C_4 - C_8 -alkexy, $di(C_4$ - C_8 -alkyl)amino or phonyl,

phenyl, indanyl or heteroaryl, wherein each phenyl, indanyl and heteroaryl is optionally substituted one or more times by halogen, -CN, C₄-C₅ alkyl, C₄-C₅ alkoxy or CF₅;

CF37

 R^{26} is C_4 C_{10} alkyl, which is optionally substituted one or more times by F, OH, C_4 C_8 alkoxy, aryloxy, C_4 C_8 alkylmercapto, C_4 C_8 alkylamino, or $di(C_4$ C_8 alkyl)amino,

optionally substituted phenyl or optionally substituted heteroaryl, wherein the optional substituents of the optionally substituted phenyl and heteroaryl are selected from one or more of the group consisting of hulogen, CN, C₃-G₃-alkyl, C₄-C₃-alkoxy and CF₃.

 R^{22} is C_4 C_{40} alkyl, which is optionally substituted one or more times by F, OH, C_4 C_8 alkoxy, aryloxy, C_4 C_8 alkylmercapto, C_4 C_8 alkylamino, or $di(C_4$ C_8 alkyl)amino, CF_{27}

optionally substituted phenyl or optionally substituted heteroaryl, wherein the optional substituents of the optionally substituted phenyl and heteroaryl are selected from one or more of the group consisting of halogen,—CN, C₄, C₃-alkyl, C₄, C₄-alkoxy and CF₃.

wherein heteroaryl is a residue of a 5-membered to 10-membered, aromatic, monocyclic or bicyclic heterocycle containing one or more heteroatoms selected from the group consisting of N, O and S;

wherein aryl is phenyl, naphth 1 yl or naphth 2 yl;

m is 0, 1 or 2; and n is 1, 2, 3 or 4;

or a stereoisomer or a mixture of stereoisomers in any ratio of the compound, or a pharmaceutically acceptable salt of the compound, stereoisomer or mixture of stereoisomers of the compound.